Date:10/22/2008

t. The Company's results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments (domestic or foreign) involving current and future products, sales growth of recently launched products, competition from other products (domestic or foreign) and difficulties or delays in manufacturing our products. In addition, sales of our products are affected by reimbursement policies imposed by third-party payors, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and health care cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development. In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candid
'/>"/>

SOURCE Amgen Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Related biology technology :

1. CNS Response Announces Fiscal Third Quarter 2007 Results
2. Avitar Reports Third Quarter Financial Results for Fiscal 2007
3. Martek to Announce Third Quarter 2007 Results on September 5, 2007
4. Third Security, LLC Hires Two New Managing Directors
5. Wyeth Sets Webcast and Conference Call for 2007 Third Quarter Earnings
6. ThirdBiotech Networking Group Launches
7. BioMed Realty Trust Declares Third Quarter 2007 Common Stock and Preferred Stock Dividends
8. PPD Announces Third Quarter 2007 Earnings Release, Webcast and Conference Call
9. Boston Scientific to Webcast Conference Call Discussing Third Quarter Financial Results
10. Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation
11. Americas Heartland Launches Third Season Highlighting Contributions of American Farmers and Ranchers